Introduction The introduction of contemporary therapies for childhood T-cell acute lymphoblastic leukemia (T-ALL) has resulted in remission rates that are closer to that of B-cell precursor (BCP) ALL but survival rates remain lower and 15-20% of children with T-ALL die from relapsed/refractory disease.1 Patients with high-risk disease or those who relapse often receive more intensive treatment, making them more susceptible to toxicity and long-term secondary complications.2 This highlights the need to investigate other agents to treat this disease
V vy, vic b sung L-Glutathione nhm lm chm qu trnh lo ha da t nhin (cng nh do tc ng tiu cc t mi trng), gip c th bn trng tr trung, trn y sc sng v lun khe mnh
Peptide therapy is not a one-size-fits-all approach
Hormonal Imbalance Whether due to aging, stress, or underlying medical conditions, BHRT restores equilibrium to estrogen, progesterone, testosterone, and adrenal hormones
Zheng Li: Writing - review & editing, Supervision, Project administration, Funding acquisition